Skip Content
You are currently on the new version of our website. Access the old version .
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 17, Issue 4

2010 August - 20 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (20)

  • Article
  • Open Access
132 Citations
574 Views
7 Pages

The Predictive Value of Pre-treatment Inflammatory Markers in Advanced Non-small-Cell Lung Cancer

  • G. Kasymjanova,
  • N. MacDonald,
  • J. S. Agulnik,
  • V. Cohen,
  • C. Pepe,
  • H. Kreisman,
  • R. Sharma and
  • D. Small

1 August 2010

Background: Accurate prediction of outcome in advanced non-small-cell lung cancer (NSCLC) remains challenging. Even within the same stage and treatment group, survival and response to treatment vary. We set out to determine the predictive value of in...

  • Article
  • Open Access
3 Citations
1,062 Views
9 Pages

1 August 2010

Background: Multiple myeloma is an incurable malignancy. Since the late 1990s, its management has changed with the introduction of novel agents. Thalidomide, which is often called a “novel” therapy, has significantly prolonged survival in multiple my...

  • Meeting Report
  • Open Access
2 Citations
801 Views
6 Pages

1 August 2010

The 5th annual Bone and The Oncologist New Updates (BONUS 5) conference, held at the National Arts Center, Ottawa, April 8–9, 2010, focused on innovative research into the mechanisms and consequences of increased bone turnover in the benign and metas...

  • Article
  • Open Access
2 Citations
1,025 Views
2 Pages

Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma

  • H. Husein–ElAhmed,
  • J.L. Callejas–Rubio,
  • R. Ortega Del Olmo,
  • R. Ríos–Fernandez and
  • N. Ortego–Centeno

1 August 2010

Melanoma is the most lethal form of skin malignancy because of its aggressive behaviour. In advanced disease, interferon alfa can be used as adjuvant therapy. However, this therapy is not free of side effects. We present a case of severe Raynaud synd...

  • Case Report
  • Open Access
19 Citations
1,075 Views
3 Pages

1 August 2010

Temozolomide (tmz) is an oral alkylating agent used during concurrent and adjuvant chemotherapy for newly diagnosed glioblastoma multiforme. Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasiona...

  • Article
  • Open Access
12 Citations
903 Views
6 Pages

Malignant Melanoma Metastatic to the Larynx: Treatment and Functional Outcome

  • B.G. Lanson,
  • N. Sanfilippo,
  • B. Wang,
  • D. Grew and
  • M.D. DeLacure

1 August 2010

The review considers management strategies for malignant melanoma metastatic to the larynx. This rare clinical entity lacks clear treatment recommendations because extirpative surgery can often result in severe functional debilitation in patients wit...

  • Case Report
  • Open Access
10 Citations
873 Views
5 Pages

1 August 2010

Ductal carcinoma in situ (dcis) in a young man is rarely reported. Our patient, a 25-year-old man, presented with apparent symptomatic unilateral gynecomastia. He has a strong history of cancer on both the maternal and paternal sides of his family, i...

  • Article
  • Open Access
26 Citations
1,245 Views
14 Pages

Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality

  • Su. Verma,
  • S. Lavasani,
  • J. Mackey,
  • K. Pritchard,
  • M. Clemons,
  • S. Dent,
  • J. Latreille,
  • J. Lemieux,
  • L. Provencher and
  • D. Rayson
  • + 3 authors

1 August 2010

Breast cancer positive for HER2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the stand...

  • Article
  • Open Access
6 Citations
870 Views
8 Pages

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

  • Zahra Kassam,
  • H. MacKay,
  • C. A. Buckley,
  • S. Fung,
  • M. Pintile,
  • A. Oza,
  • J. Brierley,
  • C. Swallow,
  • B. Cummings and
  • J. Ringash
  • + 5 authors

1 August 2010

Objective: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcin...

  • Article
  • Open Access
38 Citations
1,245 Views
7 Pages

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence

  • J. Younus,
  • S. Verma,
  • J. Franek,
  • N. Coakley and
  • the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care

1 August 2010

Question: Is sunitinib malate—marketed as Sutent (Pfizer Canada, Kirkland, QC)—superior to placebo or other interventions for primary outcomes of interest in adult patients with gastrointestinal stromal tumour (GIST) who have developed resistance or...

  • Article
  • Open Access
48 Citations
1,158 Views
6 Pages

Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey

  • S. Saibil,
  • B. Fitzgerald,
  • O.C. Freedman,
  • E. Amir,
  • J. Napolskikh,
  • N. Salvo,
  • G. Dranitsaris and
  • M. Clemons

1 August 2010

Introduction: With the widespread use of sequential anthracycline/taxane–based chemotherapy for early-stage breast cancer, clinicians are becoming rapidly aware of toxicities associated with those regimens. Despite the low incidence reported in the l...

  • Article
  • Open Access
8 Citations
879 Views
4 Pages

1 August 2010

Encouraging data for targeted therapy in head-and-neck squamous cell carcinoma are opening new options for treatment. Phase III trials of cetuximab, an antibody directed against the epidermal growth factor receptor (EGFR) have demonstrated benefit in...

  • Article
  • Open Access
725 Views
3 Pages

1 August 2010

Although many people welcome the recent move by the United States to give its Food and Drug Administration (FDA) the authority to regulate the content of tobacco, some worry that such regulation constitutes unwarranted interference with the freedom o...

  • Article
  • Open Access
49 Citations
1,535 Views
9 Pages

1 August 2010

Introduction: A growing number of psychosocial interventions are being offered to cancer patients during and after their medical treatment. Here, we examined whether Mindfulness-Based Stress Reduction (MBSR), a stress management course, helps women t...

  • Article
  • Open Access
12 Citations
1,052 Views
6 Pages

1 August 2010

Giant cell tumour (GCT) of bone is a locally aggressive benign tumour. It can, however, undergo dedifferentiation, either de novo or secondarily after local recurrence or radiation. Whether spontaneously occurring or induced by previous irradiation,...

  • Article
  • Open Access
23 Citations
1,123 Views
8 Pages

Evaluating the Impact on Quality of Life of Chemoradiation in Gastric Cancer

  • Zahra Kassam,
  • H. MacKay,
  • C.A. Buckley,
  • S. Fung,
  • M. Pintile,
  • J. Kim and
  • J. Ringash

1 August 2010

Objective: Our phase I study prospectively evaluated quality of life (QOL) in patients undergoing adjuvant chemoradiation for gastric adenocarcinoma. Methods: Thirty-three patients receiving radiotherapy (45 Gy in 25 fractions), together with 12 week...

  • Article
  • Open Access
47 Citations
1,894 Views
9 Pages

1 August 2010

Objective: Using an interview-guided survey, our descriptive study aimed to document the extent to which cancer patients perceive they are involved in making treatment decisions and the factors that influence patient involvement. Patients and methods...

  • Article
  • Open Access
311 Citations
5,088 Views
19 Pages

Prophylaxis and Management of Acute Radiation-Induced Skin Reactions: A Systematic Review of the Literature

  • N. Salvo,
  • E. Barnes,
  • J. van Draanen,
  • E. Stacey,
  • G. Mitera,
  • D. Breen,
  • A. Giotis,
  • G. Czarnota,
  • J. Pang and
  • C. De Angelis

1 August 2010

Radiation therapy is a common treatment for cancer patients. One of the most common side effects of radiation is acute skin reaction (radiation dermatitis) that ranges from a mild rash to severe ulceration. Approximately 85% of patients treated with...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729